Sana Biotechnology Releases Initial Clinical Findings Demonstrating SC291, an Off-the-Shelf CAR T Treatment Targeting CD19, Remains Undetected by a Functional Immune System.

Benitec Biopharma has reported initial dosing in an early-stage trial for its genetic treatment prospect, BB-301, aimed at tackling Oculopharyngeal Muscular Dystrophy.

Ambrx Reports Progress on APEX-01 Trial, a Phase 1 / 2 Study Assessing Increasing Doses of ARX517, Its Own PSMA-Directed Antibody-Drug Conjugate, in Advanced Prostate Cancer Unresponsive to Hormonal Therapy.

uniQure N.V., a leader in gene therapy, has announced FDA approval of its IND application for AMT-191 to treat severe medical conditions.

BioVie Inc., a biopharmaceutical firm focusing on neurological, neurodegenerative, and severe liver diseases, reported positive initial results from its Phase 3 trial of NE3107 in mild to moderate Alzheimer’s patients.

Carisma Therapeutics Inc. has confirmed that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for their novel product, CT-0525.

Bio-Thera Solutions has reported encouraging outcomes from its pivotal Phase 3 clinical trial involving BAT2206, a candidate biosimilar for Stelara®.

Halia Therapeutics Reveals Promising Initial Clinical Outcomes for Drug HT-6184 during the Fifth Summit on Inflammasome Treatment Strategies.

OncoResponse, a clinical-stage biotech innovator specializing in immunotherapy derived from elite cancer survivors, announced the first dosing in a Phase 1/2 trial of OR502.

Opsidio has initiated dosing of the initial participant in a Phase 2a study evaluating OpSCF for the treatment of moderate to severe eczema.

ASC Therapeutics has reported the inaugural administration to a patient in their Phase I/IIa study for their prime drug, ASC618, conducted at Arkansas Children's Hospital.

Longboard Pharmaceuticals, Inc., a company focused on developing new treatments for neurological conditions, has announced the start of a Phase 1 trial. This randomized, double-blind, placebo-controlled study will assess their drug candidate, LP659, in a Single Ascending Dose (SAD) format.